News
OTLK
1.520
-0.65%
-0.010
Weekly Report: what happened at OTLK last week (0421-0425)?
Weekly Report · 1d ago
Weekly Report: what happened at OTLK last week (0414-0418)?
Weekly Report · 04/21 12:23
Weekly Report: what happened at OTLK last week (0407-0411)?
Weekly Report · 04/14 12:08
Outlook Therapeutics Approves Retention Incentive for CFO
TipRanks · 04/11 22:22
OUTLOOK THERAPEUTICS - FDA DETERMINED CLASS 2 REVIEW FOR OUTLOOK THERAPEUTICS' BLA FOR ONS-5010- SEC FILING
Reuters · 04/08 21:01
Outlook Therapeutics gets FDA review acceptance for wet AMD treatment
Seeking Alpha · 04/08 14:42
Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD
NASDAQ · 04/08 13:10
Outlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010
TipRanks · 04/08 12:51
OUTLOOK THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF AUGUST 27, 2025
Reuters · 04/08 12:45
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Barchart · 04/08 07:45
Weekly Report: what happened at OTLK last week (0331-0404)?
Weekly Report · 04/07 12:07
Weekly Report: what happened at OTLK last week (0324-0328)?
Weekly Report · 03/31 12:24
Weekly Report: what happened at OTLK last week (0317-0321)?
Weekly Report · 03/24 12:07
Outlook Therapeutics files to sell 21.72M shares of common stock for holders
TipRanks · 03/20 21:05
OUTLOOK THERAPEUTICS FILES PROSPECTUS COVERING OFFER & RESALE BY SELLING STOCKHOLDERS OF UP TO 21.7 MLN SHARES OF COMMON STOCK- SEC FILING
Reuters · 03/20 21:03
Outlook Therapeutics management to meet virtually with BTIG
TipRanks · 03/20 15:50
Weekly Report: what happened at OTLK last week (0310-0314)?
Weekly Report · 03/17 12:22
Weekly Report: what happened at OTLK last week (0303-0307)?
Weekly Report · 03/10 12:24
Weekly Report: what happened at OTLK last week (0224-0228)?
Weekly Report · 03/03 12:22
Based on the provided financial report, the title of the article is: "OUTLOOK THERAPEUTICS, INC. FORM 10-Q FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2024
Press release · 03/02 05:11
More
Webull provides a variety of real-time OTLK stock news. You can receive the latest news about Outlook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.